证券代码：002589 证券简称：瑞康医药 公告编号：2025-038 瑞康医药集团股份有限公司 关于公司董事、副总裁辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）董事会收到公司董事、副 总裁韩春林先生提交的书面辞职报告。韩春林先生因个人原因决定申请辞去公司 董事、副总裁职务以及公司及子公司的所有其他职务，辞职后将不再担任公司及 控股子公司任何职务。 根据《公司法》《公司章程》相关规定，韩春林先生的辞职不会导致公司董 事人数低于法定人数，不会影响董事会及董事会专门委员会正常运作和公司正常 生产经营。韩春林先生的辞职报告自送达公司董事会之日起生效。公司董事会将 根据《公司章程》等相关规定尽快进行董事补选工作。 公司董事会对韩春林先生在任职期间为公司发展所做出的贡献表示衷心感 谢。 特此公告。 瑞康医药集团股份有限公司 董 事 会 2025 年 7 月 14 日 1 截至本公告披露日，韩春林先生未持有公司股票，不存在未履行的承诺事项。 ...

Core Viewpoint - The simultaneous announcement of a share buyback and the detention of a senior executive at Ruikang Pharmaceutical has raised significant concerns in the capital market, particularly regarding a controversial related-party transaction that occurred six months prior [1]. Group 1: Controversial Acquisition - Ruikang Pharmaceutical announced the acquisition of 76.01% of Zhejiang Hengjiu Medical Equipment for 151 million yuan, despite the target company having zero revenue and a net loss of 6.81 million yuan in the first eight months of 2024 [2]. - The acquisition price represented a nearly 10-fold premium over the target company's net asset value of 18.22 million yuan, with an assessed value of 239.5 million yuan [2]. - The actual controller of the transaction counterpart, Yantai Hengyue, is linked to senior executives including Li Zhe, indicating a typical related-party transaction [2]. Group 2: Executive Detention and Background - Li Zhe, the detained executive, has a financial background with experience at major institutions and a relatively low annual salary of 403,500 yuan, yet he was deeply involved in the controversial acquisition [3]. - Li Zhe controls Yantai Hengyue through Hangzhou Huaheng Investment Management Co., and the acquisition included a three-year profit commitment of 56 million yuan from 2027 to 2029, despite the core product still being in the development stage [3]. Group 3: Financial Performance and Challenges - Ruikang Pharmaceutical has faced a dramatic decline in revenue, dropping from 27.23 billion yuan in 2020 to 7.966 billion yuan in 2024, a decrease of over 70% [4]. - The company has reported cumulative losses of 1.496 billion yuan from 2021 to 2024, with a further 44.75% decline in net profit in the first quarter of 2025 [4]. - Regulatory warnings have been frequent, with the company and its executives being recorded in integrity files for concealing 460 million yuan in related-party capital increases and financial support [4]. Group 4: Market Reactions and Future Outlook - As of June 30, Ruikang Pharmaceutical spent 60.39 million yuan to repurchase 20.44 million shares in an attempt to instill confidence in the market [4]. - Investors are particularly concerned about the connection between Li Zhe's detention and the premium acquisition, the feasibility of the zero-revenue target meeting its profit commitments, and the source of funding for the company's transformation after four consecutive years of losses [4][5].

Group 1 - Liu Zhongliang, former president and party secretary of the Shanyang County People's Hospital, was sentenced to two and a half years in prison for accepting bribes totaling approximately 1.262 million yuan [2][3][4] - The bribes were received from 16 individuals, including a manager from a subsidiary of Ruikang Pharmaceutical, to gain advantages in medical equipment procurement and supply of consumables [2][5][6] - Ruikang Pharmaceutical's subsidiary, Ruikang Pharmaceutical (Shaanxi) Medical Device Co., Ltd., was implicated in the bribery case, although the company denied any knowledge of the alleged bribe [7][8] Group 2 - Ruikang Pharmaceutical is a comprehensive medical service provider listed on the A-share market, with a peak revenue exceeding 35 billion yuan in 2019, but has faced a continuous decline in revenue, reporting around 8 billion yuan in 2024 [7] - The company has experienced a net profit loss for four consecutive years, with a reported loss of 128 million yuan in 2024 [7] - Recently, Ruikang Pharmaceutical's board member and vice president was placed under investigation, indicating potential ongoing issues within the company's management [8]

Core Viewpoint - The recent detention of a senior executive at Ruikang Pharmaceutical has raised concerns about the company's governance and financial practices, particularly in light of a controversial acquisition that occurred earlier this year [2][3][4]. Group 1: Executive Detention and Governance - Ruikang Pharmaceutical's board secretary and vice president, Li Zhe, has been detained by the Jinan Municipal Supervisory Committee, but the company claims that its governance structure remains intact and operations are unaffected [2][3]. - The responsibilities of the board secretary are temporarily assumed by Wang Xiuting, the securities affairs representative [2]. Group 2: Controversial Acquisition - On the same day as the detention announcement, Ruikang disclosed its share buyback progress, indicating an attempt to convey stability to the market [2]. - In February 2025, Ruikang announced a contentious acquisition of 76.01% of Zhejiang Hengjiu Medical Equipment Co. for 151 million yuan, despite the target company reporting zero revenue and a loss of 6.81 million yuan in the first eight months of 2024 [4][5]. - The acquisition price represents nearly a tenfold premium over the target company's book value of 18.2186 million yuan as of August 31, 2024, raising questions about the valuation and the motivations behind the deal [5][6]. Group 3: Financial Performance and Challenges - Ruikang's financial performance has been deteriorating, with revenue dropping from 27.23 billion yuan in 2020 to 7.966 billion yuan in 2024, a decline of over 70% [8]. - The company has reported losses for four consecutive years, totaling 1.496 billion yuan, with a single-year loss of 128 million yuan in 2024 [8][9]. - The first quarter of 2025 showed a further revenue decline of 12.98% year-on-year, with a net profit decrease of 44.75% [9]. Group 4: Strategic Response and Market Concerns - In response to ongoing challenges, Ruikang announced a comprehensive reform plan in February 2025, focusing on building a full industry chain in traditional Chinese medicine and expanding its medical device product lines [9]. - However, market skepticism remains due to the company's history of frequent related-party transactions and the significant capital requirements for its strategic transformation, which may not be sustainable given its recent financial performance [9].

Core Viewpoint - The recent announcement by Ruikang Pharmaceutical Group indicates significant governance issues, particularly involving the company's board secretary and vice president, Li Zhe, who has been placed under detention by the Jinan Municipal Jiyang District Supervisory Committee due to previous disclosure violations [1][2]. Group 1: Governance and Management Changes - Li Zhe has been involved in multiple governance issues, including receiving a warning from the Shandong Securities Regulatory Bureau for failing to disclose major litigation and related party transactions in a timely manner [2][3]. - Following Li Zhe's detention, the company has appointed Wang Xiuting as the acting board secretary, ensuring that the board and supervisory committee continue to operate normally [1][2]. Group 2: Financial Performance and Risks - Ruikang Pharmaceutical has faced declining financial performance, with revenues decreasing from 272.3 billion in 2020 to 79.66 billion in 2024, representing a cumulative decline of 70.7% over the five-year period [6]. - The company reported a net profit of 2.61 billion in 2020, which turned into a loss of 18.31 billion in 2022, and has accumulated nearly 1.5 billion in losses from 2021 to 2024 [6]. Group 3: Controversial Transactions - A controversial related party transaction involving the acquisition of a 76.01% stake in Zhejiang Hengjiu Medical Equipment Co. for 1.51 billion has raised concerns due to the high valuation of the target company, which has reported zero revenue and significant losses in recent years [4][5]. - The acquisition's rationale has been questioned, particularly given the company's ongoing financial struggles and the potential for conflicts of interest among executives involved in the transaction [5][6].

IPO Dynamics - Luxshare Precision (002475.SZ) is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and financing capabilities. The details are yet to be confirmed, and the issuance will not change the control of the company [2] Corporate Governance - New Hope announced that independent director Peng Long is under disciplinary review and investigation for serious violations. This will not significantly impact the company's operations [3] - Digital China (000034.SZ) also reported that independent director Peng Long is under similar scrutiny, with no impact on daily management [10] Financing Activities - CITIC Securities (601066.SH) received approval from the China Securities Regulatory Commission to publicly issue perpetual subordinated bonds totaling up to 20 billion yuan. The approval is valid for 24 months [5] Mergers and Acquisitions - Hainan Highway (000886.SZ) plans to acquire a 51.0019% stake in Jiaokong Petrochemical, which will make it a subsidiary and is expected to constitute a major asset restructuring [7] Legal Matters - Tianci Materials (002709.SZ) has filed a lawsuit for trade secret infringement against several companies, claiming economic losses of 887 million yuan and legal fees of 1.15 million yuan [11] Corporate Announcements - Xue Ren Group (002639.SZ) has changed its stock name from "Xue Ren Shares" to "Xue Ren Group" to align with its group development strategy [13] - Guotian Group (002482.SZ) announced the resignation of Chairman Yu Qi due to work adjustments, which will not affect the company's operations [14] - Jiangnan Water (601199.SH) reported that shareholder Lianan Life increased its stake by 4.699 million shares, representing a 5.03% increase, without changing the major shareholder structure [15]

【导读】瑞康医药董事、董事会秘书及副总裁李喆被采取留置措施 中国基金报记者 李智 7月2日晚间，瑞康医药发布公告称，公司于7月1日收到济南市济阳区监察委员会的通知，公 司董事、董事会秘书及副总裁李喆被济南市济阳区监察委员会实施留置措施。 因李喆在留置期间不能履行董事会秘书职责，为保证公司的正常运作，根据相关规定，在李 喆被留置期间，由公司证券事务代表王秀婷代行董事会秘书职责。目前，公司已对相关工作 进行了妥善安排。 瑞康医药表示，公司拥有完善的治理结构和内部控制机制，除李喆外，董事、监事和其他高 级管理人员均正常履职。本事项不会对公司正常生产经营产生重大影响。 公开资料显示，李喆现年39岁，硕士学历，历任加拿大永明金融蒙特利尔分部理财顾问、加 拿大帝国商业银行多伦多分部基金管理专员、国金证券上海承销保荐分公司投行项目经理， 现任瑞康医药董事、董事会秘书、副总裁。 版权声明 《中国基金报》对本平台所刊载的原创内容享有著作权，未经授权禁止转载，否则将追究法律责任。 授权转载合作联系人：于先生（电话：0755-82468670） 公告显示，李喆2024年年薪为40.35万元。 | 姓名 | 服务 | 任昭日期 | ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-036 瑞康医药集团股份有限公司 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，回购期间，公司应在每个月的前三个交易日 内披露截至上月末的回购进展情况。现将公司截至上月末的回购股份的进展情况 公告如下： 一、回购股份的进展情况 截至 2025 年 6 月 30 日，公司通过股份回购专用证券账户以集中竞价方式回 购公司股份 2,044.6517 万股，占公司目前总股本的 1.36%，最高成交价 3.08 元/ 股，最低成交价 2.75 元/股，成交总金额 6,039.63 万元（不含交易费用）。本次 回购股份符合公司既定的回购股份方案及相关法律法规的要求。 二、其他说明 1 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自 ...

Core Viewpoint - The company announced that its director, board secretary, and vice president Li Zhe has been subjected to detention measures by the Jinan Municipal Jiyang District Supervisory Committee, but this will not significantly impact the company's normal operations [1] Group 1 - Li Zhe is currently under detention, and during this period, the company's securities affairs representative Wang Xiuting will act as the board secretary [1] - The company maintains a sound governance structure and internal control mechanisms, with all other directors, supervisors, and senior management continuing to perform their duties normally [1] - The production and operational order of the company and its subsidiaries remain normal, indicating stability in business activities despite the situation [1]

Core Viewpoint - The announcement details the profit distribution plan for Ruikang Pharmaceutical Group Co., Ltd. for the fiscal year 2024, which has been approved by the shareholders' meeting held on May 16, 2025, and specifies the cash dividend distribution without issuing new shares [1][2]. Summary by Sections Profit Distribution Plan - The total amount for profit distribution is calculated as 5,937,055.82 yuan, based on a distribution ratio of 0.004 yuan per share for 1,484,263,954 shares [1]. - The cash dividend per share after the distribution will be adjusted to 0.0039456 yuan, calculated as the total cash dividend divided by the total share capital [1]. Changes in Share Distribution - If the total number of shares entitled to profit distribution changes due to convertible bonds, share buybacks, stock option exercises, or new shares from refinancing before the implementation of the profit distribution plan, the total dividend amount will be adjusted accordingly based on the number of shares on the record date [2]. Rights and Dates - The record date for the profit distribution is set for July 7, 2025, and the ex-dividend date is July 8, 2025 [2][3]. - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies [3]. Distribution Recipients - The recipients of the profit distribution will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the record date [3]. Consultation Information - For inquiries regarding the profit distribution, shareholders can contact the company's securities affairs department at the provided address and phone number [3][4].